Quest Diagnostics Incorporated

DGX Healthcare Diagnostics & Research

Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 14.7%, free cash flow grew 5.28% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

235.00 4.15 −1.74%
Market cap
$26.4B
P/E
24.6×
Fwd P/E
20.8×
Dividend yield
1.44%
F-score
8/9
Altman Z
3.15
Beneish M
−2.65
Dividend safety
85/100

Quest Diagnostics Incorporated (DGX) Revenue

Alert me on Revenue

Quest Diagnostics Incorporated's revenue for fiscal 2025 was $11.0B, up 11.8% from $9.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was $11.6B. Over the past ten years it has ranged from $7.2B (fiscal 2016) to $11.0B (fiscal 2025) — the current reading is the highest in ten years. Quest Diagnostics Incorporated ranks 5th of 50 Diagnostics & Research companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $11.0B 11.78%
FY2024 $9.9B 6.70%
FY2023 $9.3B (6.38%)
FY2022 $9.9B (8.39%)
FY2021 $10.8B 14.32%
FY2020 $9.4B 22.15%
FY2019 $7.7B 2.59%
FY2018 $7.5B 1.74%
FY2017 $7.4B 2.61%
FY2016 $7.2B (3.72%)

Quarterly newest first

Period Revenue Change
Jun 2026 $3.0B 5.11%
Mar 2026 $2.9B 3.17%
Dec 2025 $2.8B (0.36%)
Sep 2025 $2.8B 1.99%
42 more quarters

Against its own ten years

Low $7.2B High $11.0B
Ten-year median $9.3B
Current reading's percentile 100

Revenue against peers

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on DGX